首页> 中文期刊> 《中国实用口腔科杂志》 >CCR5拮抗剂Maraviroc对唾液腺腺样囊性癌细胞生物学活动影响及其临床意义研究

CCR5拮抗剂Maraviroc对唾液腺腺样囊性癌细胞生物学活动影响及其临床意义研究

         

摘要

目的 探讨CCR5拮抗剂Maraviroc对人唾液腺腺样囊性癌(SACC)细胞运动、趋化、侵袭及增殖的影响.方法 采用体外划痕、趋化、侵袭及增殖实验,观察Maraviroc对SACC-83和SACC-LM细胞的运动、趋化、侵袭及增殖能力的影响.结果 与对照组比较,加入Maraviroc预处理的实验组细胞划痕模型愈合速度明显降低;趋化和侵袭实验中,穿越多聚碳酸酯膜的细胞数明显减少;增殖实验结果显示可明显抑制SACC-83和SACC-LM细胞增殖.结论 Maraviroc可能是一种新的靶向抗肿瘤药物,小分子剂量的临床应用可能会抑制SACC的发展.%Objective To study the role of the CCR5 antagonists Maraviroc in the migration,chemotaxis,invasion and proliferation of human salivary adenoid cystic carcinoma.Methods Scratches、migration、invasion and MTT assays were performed to detect the migration,chemotaxis,invasion and proliferation of SACC-83 and SACC-LM in vitro.Results Compared with control group,the experimental group which was pretreated by CCR5 inhibitor Maraviroc had lower recuperability in cell scratch model.The number of cells which were blocked by inhibitor decreased significantly on the lower surface of the filters which were fixed in methanol in migration and invasion assays.And proliferation experiment results show that the muhiplication capacity of SACC-83 and SACC-LM were obviously inhibited by Maraviroc.Conclusion Maraviroc may be a kind of new targeted anti-tumor drugs and small-molecule antagonists of CCR5 could inhibit the development of salivary gland adenoid cystic carcinoma.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号